Early objective response may not be a prognostic factor of survival for patients with metastatic urothelial carcinoma: from a retrospective analysis of a cohort of 113 patients

Guilhem Roubaud 1, * Véronique Brouste 2 Phillipe Beuzeboc 3 Aude Fléchon 4 Diego Tosi 5 Sandrine Lavau-Denes 6 Christine Chevreau 7 Stéphane Culine 8 Stéphane Oudard 9 Amandine Quivy 1 Philippe Pourquier 5 Nadine Houédé 10, 1
* Auteur correspondant
1 Service d'Oncologie Médicale [Bordeaux]
2 Institut Bergonié Bordeaux
3 Service d'oncologie médicale [CHU Pitié-Salpêtrière]
4 Service d'Oncologie Médicale
5 IRCM - U1194 Inserm - UM - Institut de Recherche en Cancérologie de Montpellier
6 Service d'Oncologie médicale [CHU Limoges]
7 Institut Claudius Regaud
8 Service d'oncologie médicale
9 Service d'oncologie médicale [CHU HEGP]
10 Service d'Oncologie Médicale
Abstract : Background: This study aims to better define prognostic factors for patients with metastatic urothelial carcinoma (mUC), and to identify patients who will benefit from first-line cisplatin-based chemotherapy. We test the hypothesis that early objective response (EOR), defined as the occurrence of an objective response following 2 or 3 courses of chemotherapy, could be a prognostic factor for overall survival (OS) and thus be used to guide treatment decisions. Data from 113 patients with evaluable mUC receiving first-line cisplatin-based treatment between January 2004 and December 2006 was collected retrospectively from prospectively-maintained databases across seven French cancer centers. Clinical factors potentially associated with survival and EOR were analyzed in univariate and multivariate analysis. Results: One hundred three patient records were complete and available for inclusion in the multivariate model. Four factors were independently associated with OS: Performance status 1 and 2 (HR 2.3 [95 % CI 1.3–3.9], p = 0.002; HR 3.4 [95 % CI 1.6–7.2], p = 0.001 respectively); presence of visceral metastases (HR 2.2 [95 % CI 1.3–3.9], p = 0.004); abnormal hemoglobin levels (HR 1.7 [95 % CI 1.01–2.8], p = 0.045); disease progression (HR 10.1 [95 % CI 4.2–24.1], p < 0.001).
Keywords : Cisplatin-based regimen Metastatic urothelial carcinoma Objective response Prognostic factors Survival
Type de document :
Article dans une revue
Journal of Negative Results in BioMedicine, BioMed Central, 2015, 14 (1), pp.18. 〈10.1186/s12952-015-0037-5〉
Liste complète des métadonnées

Littérature citée [24 références]  Voir  Masquer  Télécharger
http://www.hal.inserm.fr/inserm-01264496
Contributeur : Bmc Bmc <>
Soumis le : vendredi 29 janvier 2016 - 12:42:58
Dernière modification le : lundi 17 septembre 2018 - 15:55:47
Document(s) archivé(s) le : vendredi 11 novembre 2016 - 20:40:56

Fichiers

art%3A10.1186%2Fs12952-015-003...
Publication financée par une institution

Identifiants

Collections

ICR | BERGONIE | VALDAURELLE | UNIV-PARIS5 | FNCLCC | USPC | UNIV-MONTPELLIER | BS

Citation

Guilhem Roubaud, Véronique Brouste, Phillipe Beuzeboc, Aude Fléchon, Diego Tosi, et al.. Early objective response may not be a prognostic factor of survival for patients with metastatic urothelial carcinoma: from a retrospective analysis of a cohort of 113 patients. Journal of Negative Results in BioMedicine, BioMed Central, 2015, 14 (1), pp.18. 〈10.1186/s12952-015-0037-5〉. 〈inserm-01264496〉

Exporter

BibTeX TEI DC DCterms EndNote

Partager

Métriques

Consultations de la notice

112

Téléchargements de fichiers

141

Contact

support.ccsd.cnrs.fr
hal.support@ccsd.cnrs.fr
Logo CCSD